Which segment accounted for the largest North America Cell & Gene Therapy Manufacturing Services Market share?

The oncology segment accounts for the largest share of the North America Cell & Gene Therapy Manufacturing Services Market. High demand for personalized cancer treatments, including CAR-T cell therapies, and substantial investments from biopharmaceutical companies are underpinning segment dominance and fostering advancements in targeted cell and gene therapies for cancer.

What are the factors driving the North America Cell & Gene Therapy Manufacturing Services Market?

Key drivers include rising prevalence of chronic and rare diseases, technological advancements, and strategic partnerships. For example, Catalent Inc. has expanded its manufacturing capacity through acquisitions and collaborations to meet growing demand from biopharma companies seeking reliable, large-scale, and specialized cell and gene therapy manufacturing services in the region.

Which type accounted for the largest North America Cell & Gene Therapy Manufacturing Services Market share?

Cell therapy manufacturing services hold the largest market share in North America, due to the expanding pipeline of cell-based therapeutics, particularly CAR-T therapies and stem cell treatments. These therapies require specialized manufacturing, driving growth and investment from service providers to support clinical development and commercialization.

Home Healthcare

North America Cell & Gene Therapy Manufacturing Services Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Q: Who are the key players in North America Cell & Gene Therapy Manufacturing Services Market industry?

The key players in the North America Cell & Gene Therapy Manufacturing Services Market include Lonza Group, Thermo Fisher Scientific, Catalent Inc., WuXi Advanced Therapies, and Charles River Laboratories. These companies offer comprehensive manufacturing solutions, leveraging advanced technologies and deep expertise to support the development and commercial production of cell and gene therapies.

North America Cell & Gene Therapy Manufacturing Services Market: by Type (Allogeneic, Autologous, Viral Vector, Non-viral Vector, Plasmid DNA, Others), Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases, Infectious Diseases, Others), Distribution Channels (Direct Tenders, Third-Party Distributors, Online Platforms, Others), Technology (Gene Editing, Cell Expansion, Viral Vector Production, Cryopreservation, Automation, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20518

North America Cell & Gene Therapy Manufacturing Services Market (2025-2035)

The North America Cell & Gene Therapy Manufacturing Services Market encompasses solutions for the efficient, compliant manufacturing of novel therapies targeting genetic and cellular mechanisms, addressing unmet medical needs in diverse indications. These services include allogeneic and autologous therapy production, viral and non-viral vector manufacturing, plasmid DNA production, and specialized support for various therapeutic applications. Major regional growth is driven by increasing approvals of advanced therapies, strategic partnerships among biopharmaceutical companies, and investments in next-generation manufacturing technologies. The market is witnessing rapid adaptation of automation and digitalization to enhance throughput, scalability, and regulatory adherence. This robust landscape supports the evolving needs of oncology, rare, neurological, and cardiovascular disease therapy development in North America.

Latest Market Dynamics

Key Drivers

Rising FDA approvals and clinical trial activities for cell and gene therapies in North America are accelerating demand for specialized manufacturing services. For instance, in June 2024,

Adoption of automation and digital bioprocessing is enhancing the scalability and consistency of cell and gene therapy manufacturing. WuXi AppTec launched a new digital manufacturing suite in June 2024 to optimize operations and turnaround time.
Increasing outsourcing of plasmid DNA and viral vector production to contract manufacturers—Lonza reported a 40% increase in viral vector contracts in early 2024, indicating a shift toward deeper collaboration with therapy developers.

Emerging demand for personalized therapies, especially in oncology and rare diseases, is enabling service providers to diversify portfolios. Catalent expanded its California facility in July 2024 to support rapid manufacturing of autologous therapies.
Expansion into allogeneic off-the-shelf therapies provides scalable opportunities—Fujifilm Diosynth Biotechnologies initiated a new project for allogeneic CAR-T production in July 2024.

Manufacturing scale-up and supply chain complexities remain persistent challenges for service providers—Charles River Laboratories reported delays in cell therapy batch releases due to raw material shortages in June 2024.
Stringent regulatory and quality compliance requirements demand sophisticated systems and skilled labor. Oxford Biomedica highlighted increased regulatory scrutiny leading to extended project timelines in 2024.

In 2025, allogeneic therapies capture the largest market share in North America, driven by their scalability and potential for off-the-shelf solutions. Autologous therapies maintain a significant segment, particularly for personalized oncology applications. Viral vector manufacturing also remains vital, given its central role in enabling gene therapy development across therapeutic areas. The distribution reflects a diversified marketplace focused on both innovative, patient-customized solutions and broader-access products supporting multiple disease categories.

Oncology represents the dominant application area for cell and gene therapy manufacturing services in North America for 2025, reflecting the growing clinical pipeline and payer support for advanced cancer treatments. Cardiovascular diseases and rare disorders are gaining traction due to increased gene therapy approvals and the success of precision medicine initiatives. Neurological and infectious diseases continue to present growth opportunities, as new indications enter late-stage development following robust clinical results.

The North America Cell & Gene Therapy Manufacturing Services Market revenue is projected to witness exponential growth during 2020-2035. Supported by accelerating FDA approvals, investment flows, and expanding contract manufacturing capacities, the market is expected to rise from USD 1,600 Million in 2020 to over USD 8,300 Million by 2035. Key growth drivers include the advancement of personalized medicine and consistent investment in scalable manufacturing platforms to address rising demand across major therapeutic areas.

Year-over-year growth in the North America Cell & Gene Therapy Manufacturing Services Market remains robust, averaging 12-14% across the projection period. The highest spikes are observed between 2025 and 2030, primarily due to expanding commercialization of gene-editing therapies and larger patient populations accessing these modalities. Growth moderates slightly post-2030 as the market matures, driven by continued innovation and new applications.

The US dominates the North American cell and gene therapy manufacturing services market, accounting for an estimated 74% share in 2025 due to significant infrastructure, investments, and the presence of major industry players. Canada follows with an 18% share, reflecting strong government support and expanding biotech clusters. Mexico captures 8%, with ongoing initiatives to build manufacturing capabilities in collaboration with US and Canadian firms.

Biopharmaceutical companies represent the largest buyer segment for manufacturing services (45%), driven by both established firms and emerging biotech players leveraging contract services for clinical and commercial production. Academic and research institutes (28%), hospitals and specialty clinics (17%), and others (10%) follow, each playing a pivotal role in preclinical research and early-stage clinical trial activities.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	2600
Regions	US, Canada, Mexico
Segments	By Type (Allogeneic, Autologous, Viral Vector, Non-viral Vector, Plasmid DNA, Others); By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases, Infectious Diseases, Others); By Technology (Gene Editing, Cell Expansion, Viral Vector Production, Cryopreservation, Automation, Others); By Distribution Channels (Direct Tenders, Third-Party Distributors, Online Platforms, Hospital Pharmacies, Retail Pharmacies, Others); By Organization Size (Small, Medium, Large)
Players	Thermo Fisher Scientific, Lonza, Catalent, WuXi AppTec, Charles River Laboratories, Oxford Biomedica, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Bluebird Bio, Cell and Gene Therapy Catapult, uniQure, Novartis, BioNTech, Bristol Myers Squibb, Editas Medicine

July 2024: Thermo Fisher Scientific expanded its gene therapy manufacturing collaboration with bluebird bio for commercial-scale production.
July 2024: Catalent completed the expansion of its California facility, focusing on autologous cell therapy manufacturing.
July 2024: Fujifilm Diosynth Biotechnologies commenced construction of a new allogeneic CAR-T cell therapy facility in Texas.
June 2024: WuXi AppTec launched a cloud-based digital manufacturing suite to optimize cell and gene therapy production.
June 2024: Bristol Myers Squibb announced a significant investment to double its cell therapy manufacturing capacity in the United States.

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

North America Cell & Gene Therapy Manufacturing Services Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Cell & Gene Therapy Manufacturing Services Market (2025-2035)

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share (%) by Type, 2025

Market Share (%) by Application, 2025

Market Revenue (USD Million), 2020-2035

Market YOY (%) Growth, 2020-2035

Market Share (%) by Region, 2025

Market Share (%) by Key Players, 2025

Market Share (%) by Buyers, 2025

Study Coverage

Key Recent Developments

Frequently asked questions